The estimated Net Worth of James Priour is at least $35.7 millier dollars as of 13 April 2021. Mr Priour owns over 2,266 units of Zymeworks BC Inc stock worth over $35,731 and over the last 4 years he sold ZYME stock worth over $0.
Mr has made over 1 trades of the Zymeworks BC Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 2,266 units of ZYME stock worth $27,419 on 13 April 2021.
The largest trade he's ever made was exercising 2,266 units of Zymeworks BC Inc stock on 13 April 2021 worth over $27,419. On average, Mr trades about 755 units every 0 days since 2021. As of 13 April 2021 he still owns at least 2,953 units of Zymeworks BC Inc stock.
You can see the complete history of Mr Priour stock trades at the bottom of the page.
James Daniel Guylain Priour is the Chief Commercial Officer at Zymeworks BC Inc.
Mr Priour is 54, he's been the Chief Commercial Officer of Zymeworks BC Inc since . There are 4 older and 2 younger executives at Zymeworks BC Inc. The oldest executive at Zymeworks BC Inc is Dr. Jennifer Kaufman-Shaw L.L.B., LLB, Ph.D., 71, who is the VP of Intellectual Property.
James's mailing address filed with the SEC is C/O ZYMEWORKS INC., 1385 WEST 8TH AVENUE, SUITE 540, VANCOUVER, A1, V6H 3V9.
Over the last 6 years, insiders at Zymeworks BC Inc have traded over $15,586,802 worth of Zymeworks BC Inc stock and bought 5,881,975 units worth $49,789,204 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Capital, Llc Eco R1 et Group, Llc Green Jeremy Red.... On average, Zymeworks BC Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,629,555. The most recent stock trade was executed by Kenneth Galbraith on 5 January 2024, trading 47,666 units of ZYME stock currently worth $576,759.
zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.
Zymeworks BC Inc executives and other stock owners filed with the SEC include: